Adam Wilczega

BIOTON S.A.

Bioton SA is a listed, Poland based, innovation-driven, biotechnological company. The company's major therapeutic area is diabetes. The company offers recombinant human insulin for injection form and oral hypoglycemic drugs, including glimepiride and metformin. Other OTC products, e.g. cardiovasculars, a line of supplements, nutritional uses and cosmetics, support the diabetes franchise on the domestic market. Bioton's international insulin sales are driven by distribution alliances established in e.g. China, Russia, Ukraine and Vietnam. Company's current focus is on becoming a true global player on the insulin with a target to commence sales in new geographies for the recombinant human insulin including Africa, Middle East and South America. Bioton, through its subsidiaries has operations in Italy, India, Australia, Singapore, Switzerland, and South Korea. Key products supplied on foreign markets, apart from insulin, include e.g. growth hormone, antibiotics and drugs used in gastroenterology, immunology and oncology. Currently the Company employs over 400 people with majority located in Poland.